微信内可能无法直接打开本站。请点右上角 ··· → 在浏览器打开，或复制链接。
STAT+: FDA approves Roivant therapy for rare autoimmune disease
RSS 官方收录 · 可信分层展示
关键摘要
FDA批准Roivant旗下Lisraya治疗罕见皮肌炎，患者约4万至7万人
- Lisraya（brepocitinib）为口服日服一次新药
- 用于治疗伴肌肉无力与皮疹的罕见自身免疫病皮肌炎
- 当前标准疗法为高剂量激素及其他免疫抑制剂
AI 摘要 · 来源可核验
正文提要
The Food and Drug Administration on Thursday approved a new medicine from Roivant and its subsidiary Priovant for the treatment of dermatomyositis, a rare autoimmune disease characterized by muscle weakness and a painful skin rash.
The drug, called brepocitinib, will be marketed under the brand name Lisraya. It’s a pill taken once daily.
High doses of steroids and other immune-suppressing drugs are the current standard of care for patients with dermatomyositis, which affects between 40,000 and 70,000 people in the U.S., according to Roivant.